跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ACTRN12612000869875
ACTRN12612000869875终止2 期

An Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer’s Disease

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.0 个研究点目标入组 1,960 人开始时间: 2012年8月16日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
2 期
状态
终止
入组人数
1,960
研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
55 Years 至 85 Years（—）
性别
All

入选标准

  • •Mild to Moderate Alzheimer's Disease with an MMSE score between 15 and 26. Each subject must have a reliable and competent trial partner/caregiver who has
  • •a close relationship with the subject

排除标准

  • •evidence of vascular dementia or stroke. Other clinically relevant neurological disorder. Clinically relevant or unstable psychiatric disorders. History of hepatitis or liver disease within the previous 6 months. History of malignancy occurring within the previous five years.

研究者

相似试验

已完成
1 期
A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])Alzheimer's Disease
NCT01496170Merck Sharp & Dohme LLC32
进行中（未招募）
不适用
An Efficacy and Tolerability Study of MK-0533 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - ND
EUCTR2006-002090-47-ITMERCK SHARP DOHME100
进行中（未招募）
不适用
An Efficacy and Tolerability Study of MK-0533 in Patients with Type II Diabetes Mellitus Who Have Inadequate Glycemic Control.Type II DiabetesMedDRA version: 8.1Level: LLTClassification code 10045242Term: Type II diabetes mellitus
EUCTR2006-002090-47-HUMerck & Co., Inc.600
进行中（未招募）
不适用
An Efficacy and Tolerability Study of MK-0533 in Patients with Type II Diabetes Mellitus Who Have Inadequate Glycemic Control.Type II DiabetesMedDRA version: 7.1Level: LLTClassification code 10012613
EUCTR2006-002090-47-DEMerck & Co. Inc.600
进行中（未招募）
不适用
An Efficacy and Tolerability Study of MK-0533 in Patients with Type II Diabetes Mellitus Who Have Inadequate Glycemic Control. - 12 week study of MK - 0533 in patients with T2DMType II DiabetesMedDRA version: 7.1Level: LLTClassification code 10012613
EUCTR2006-002090-47-CZMerck & Co., Inc.600